Aurobindo Pharma 's wholly owned subsidiary Eugia Pharma Specialities Limited has announced the commercial launch of pomalidomide capsules in the United States market. The company has launched the product in multiple strengths of 1 mg, 2 mg, 3 mg and 4 mg, marking a significant entry into the oncology segment.

Product Launch Details

The newly launched pomalidomide capsules serve as a generic equivalent of Pomalyst® Capsules of BMS Pharmaceuticals Corp. Eugia Pharma Specialities Limited was one of the First-to-File (FTF) ANDA applicants for this product, providing a competitive advantage in the market entry. The product will be manufactured at Eugia Unit-I facility.

Market Opportunity and Therapeutic Use

According to IQVIA MAT data for the twelve months ending January 2026, pomalidomide capsules have an estimated market size of approximately US$ 3.3 billion in the United States. This substantial market opportunity underscores the commercial potential for generic manufacturers entering this therapeutic space.

Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone and sometimes bortezomib to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma. The availability of generic versions enhances treatment accessibility and provides cost-effective options for patients requiring this critical oncology medication.

Strategic Significance

This product launch strengthens Aurobindo Pharma's presence in the US pharmaceutical market through its subsidiary Eugia Pharma Specialities Limited. The First-to-File status provides competitive positioning in this high-value oncology segment. The introduction of pomalidomide capsules adds to the company's oncology portfolio, demonstrating continued commitment to developing and commercializing complex generic formulations in major global markets.

Aurobindo Pharma 's subsidiary facility has undergone regulatory scrutiny as the US Food and Drug Administration completed an inspection of Eugia Pharma Specialties' Unit I from February 16 to February 27.

FDA Inspection Results

The inspection of the formulation manufacturing facility, located at Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana, concluded with four observations from the regulatory authority. The company has committed to respond to the US FDA within stipulated timelines as per standard regulatory procedures.

Company Response and Impact

Aurobindo Pharma has confirmed through its regulatory filing that there is no impact on the company's financials or operations due to the inspection findings. The pharmaceutical manufacturer emphasized its commitment to maintaining the highest quality manufacturing standards across all global facilities.

Regulatory Oversight

FDA inspections are routine regulatory procedures designed to ensure pharmaceutical manufacturing facilities maintain compliance with established quality standards and manufacturing practices. The completion of this inspection represents part of the ongoing regulatory oversight process for pharmaceutical operations.

The company has assured stakeholders that it will keep stock exchanges informed of any further developments relating to this inspection. Such regulatory interactions are common in the pharmaceutical industry as companies work to maintain compliance with stringent manufacturing requirements.